Literature DB >> 23463131

Successful treatment of idiopathic recurrent pericarditis with interleukin-1 receptor antagonist (Anakinra).

Marisol Camacho-Lovillo, Ana Méndez-Santos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23463131     DOI： 10.1007/s00246-013-0663-y

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN： 0172-0643            Impact factor:   1.655


× No keyword cloud information.
  6 in total

1.  Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology.

Authors:  Bernhard Maisch; Petar M Seferović; Arsen D Ristić; Raimund Erbel; Reiner Rienmüller; Yehuda Adler; Witold Z Tomkowski; Gaetano Thiene; Magdi H Yacoub
Journal:  Eur Heart J       Date:  2004-04       Impact factor: 29.983

2.  Recurrent pericarditis: recent advances and remaining questions.

Authors:  Ralph Shabetai
Journal:  Circulation       Date:  2005-09-27       Impact factor: 29.690

3.  Efficacy of an interleukin-1β receptor antagonist (anakinra) in idiopathic recurrent pericarditis.

Authors:  Alessandra Scardapane; Antonio Brucato; Francesco Chiarelli; Luciana Breda
Journal:  Pediatr Cardiol       Date:  2012-10-07       Impact factor: 1.655

4.  Colchicine for recurrent pericarditis (CORP): a randomized trial.

Authors:  Massimo Imazio; Antonio Brucato; Roberto Cemin; Stefania Ferrua; Riccardo Belli; Silvia Maestroni; Rita Trinchero; David H Spodick; Yehuda Adler
Journal:  Ann Intern Med       Date:  2011-08-28       Impact factor: 25.391

5.  Recurrent pericarditis in children and adolescents: report of 15 cases.

Authors:  Marja Raatikka; Pirkko M Pelkonen; Jouko Karjalainen; Eero V Jokinen
Journal:  J Am Coll Cardiol       Date:  2003-08-20       Impact factor: 24.094

6.  Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease?

Authors:  Paolo Picco; Giacomo Brisca; Francesco Traverso; Anna Loy; Marco Gattorno; Alberto Martini
Journal:  Arthritis Rheum       Date:  2009-01
  6 in total
  13 in total

Review 1.  Interleukin-1 blockade for the treatment of pericarditis.

Authors:  Leo F Buckley; Michele M Viscusi; Benjamin W Van Tassell; Antonio Abbate
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2018-01-01

Review 2.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

3.  Treatment of Inflammatory Diseases with IL-1 Blockade.

Authors:  Charles A Dinarello
Journal:  Curr Otorhinolaryngol Rep       Date:  2018-03-07

4.  Management of Idiopathic Viral Pericarditis in the Pediatric Population.

Authors:  Nicholas C Schwier; Katy Stephens; Peter N Johnson
Journal:  J Pediatr Pharmacol Ther       Date:  2022-09-26

Review 5.  Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis.

Authors:  Bryan Q Abadie; Paul C Cremer
Journal:  BioDrugs       Date:  2022-05-31       Impact factor: 7.744

Review 6.  Targeting interleukin-1 in heart disease.

Authors:  Benjamin W Van Tassell; Stefano Toldo; Eleonora Mezzaroma; Antonio Abbate
Journal:  Circulation       Date:  2013-10-22       Impact factor: 29.690

Review 7.  Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism.

Authors:  Antonio Brucato; Giacomo Emmi; Luca Cantarini; Andrea Di Lenarda; Marco Gattorno; Giuseppe Lopalco; Renzo Marcolongo; Massimo Imazio; Alberto Martini; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2018-04-09       Impact factor: 3.397

Review 8.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

Review 9.  Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.

Authors:  Giuseppe Lopalco; Luca Cantarini; Antonio Vitale; Florenzo Iannone; Maria Grazia Anelli; Laura Andreozzi; Giovanni Lapadula; Mauro Galeazzi; Donato Rigante
Journal:  Mediators Inflamm       Date:  2015-02-16       Impact factor: 4.711

Review 10.  The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.

Authors:  Silvia Federici; Alberto Martini; Marco Gattorno
Journal:  Front Immunol       Date:  2013-10-31       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.